IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1516)	4/10/1998 6:13:00 PM
From: Maurice Winn	Read Replies (2) of 1762

cancernet.nci.nih.gov Thanks BobLLL from Yahoo for the reference and comments: "There are two large studies going on now on to gather more data on Rituxan. Over a thousand patients in the two. A huge list of major cancer centers participating. Unlike the Oncolym study, these studies can be confirmed on the NCI site. Look for yourself, search for Lymphoma, Adult, NonHodgins/ Phase III/ Modality: monoclonal antibody Oh, yeah, you'll also see another study of Bexxar by another group of scientists too dumb to read this thread Nothing about Oncolym. I'll leave it to the bulls to explain why this also is irrelevant. After all, what does NCI know about this stuff?" Richard, just trying to tempt you to take an interest in IDPH, TCLN and CLTR. It isn't that I don't think CD20 MAbs won't be ineffective, its just that I'm unsure that they will. Meanwhile, [to those interested], Tarken's lymphoma was strongly CD20 positive, but no Rituxan treatment anyway! Does Rituxan have such cunning that it can discriminate between CD20 on intermediate grade which has changed from low grade and is ineffective on CD20 cells which are given the somewhat arbitrary designation intermediate grade instead of low grade or indolent. Since indolent can metamorphose into intermediate, the distinction seems capricious. Surely the only thing that matters in regard to Rituxan is strongly expressed CD20. Any ideas anyone? Why is Rituxan only effective on low grade CD20? Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next